<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8070">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859547</url>
  </required_header>
  <id_info>
    <org_study_id>499H01</org_study_id>
    <nct_id>NCT00859547</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants</brief_title>
  <official_title>A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM® (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZymoGenetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZymoGenetics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and immunogenicity of recombinant
      thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and
      skin grafting in pediatric patients, newborn through 17 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety, immunogenicity, and efficacy of rThrombin have been evaluated in 5 Phase 2
      studies, 1 pivotal Phase 3 study, and 1 Phase 3b study, in surgical indications such as:
      spinal surgery, major hepatic resection, peripheral arterial bypass surgery, arteriovenous
      graft formation for hemodialysis access, and burn wound excision. Limited data currently
      exist on the effects of rThrombin exposure in pediatric patients. This Phase 4 trial aims to
      provide additional information on the use of rThrombin in children by evaluating the drug's
      safety and immunogenicity when administered as an aid to hemostasis during burn wound
      excision and skin grafting in pediatric burn patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Death, Serious Adverse Events, Treatment-related Adverse Events (AE), AEs Leading to Discontinuation, and AEs of Hypersensitivity</measure>
    <time_frame>Days 1 through 29, continuously</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs by Maximum Severity</measure>
    <time_frame>Days 1 through 29, continuously</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. Mild=asymptomatic or minor symptoms; intervention not indicated. Moderate=requiring only minimal, local, or noninvasive intervention. Severe=significant symptoms but not life-threatening; hospitalization or invasive intervention indicated. Life-threatening=indicating intensive care or urgent invasive intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Findings of Grade O or Higher in Platelet, White Blood Cell (WBC), Lymphocyte, and Neutrophil Counts</measure>
    <time_frame>Baseline and Day 29 from Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Abnormal laboratory findings were recorded as AEs when considered clinically significant (unusual for the surgical population or individual participant) by the investigator, when associated with symptoms, when requiring specific treatment, or when requiring a change in participant management.LLN=lower level of normal. Platelets: Grade 0=normal. WBC: Grade 0=normal. Lymphocytes: Grade 0=normal; Grade 1=&lt;LLN x 0.8-10^9/L. Neutrophils: Grade 0=normal; Grade 1=&lt;LLN-1.5x10^9/L; Grade 2=&lt;1.5-1.0x10^9/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Hemoglobin Levels</measure>
    <time_frame>Baseline and Day 29 from Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>LLN=lower level of normal. Grade 1=100 g/L to &lt;LLN; Grade 2=80 to &lt;100 g/L; Grade 3=65 to &lt;80 g/L; Grade 4=&lt;65 g/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Creatinine Levels</measure>
    <time_frame>Baseline and Day 29 from Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ULN=upper level of normal. Grade 0=normal; Grade 1=&gt;ULN to 1.5 x ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Elevations in the Coagulation Parameter of Activated Partial Thromboplastin Time (aPPT)of Grade 0 or Higher</measure>
    <time_frame>Baseline and Day 29 from Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ULN=upper limit of normal. Grade 0=normal; Grade 1=ULN to 1.5 x ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a High International Normalized Ratio (INR) of Prothrombin Time of Grade 0 or Higher</measure>
    <time_frame>Baseline and Day 29 from Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Grade 0=normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants WIth Positive Findings for Anti-rThrombin Product Antibody</measure>
    <time_frame>At Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody-positive was defined as seroconversion or ≥1.0 unit (≥10-fold) increase in titer compared with antibody titer at baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <arm_group>
    <arm_group_label>Recombinant thrombin (rThrombin), 1000 IU/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rThrombin, 1000 IU/mL</intervention_name>
    <description>rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.</description>
    <arm_group_label>Recombinant thrombin (rThrombin), 1000 IU/mL</arm_group_label>
    <other_name>RECOTHROM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of newborn through 17 years at time of enrollment

          -  At least 1 skin graft recipient site measuring at least 1% of total body surface area
             (TBSA)

          -  Total initial burn wounds estimated to measure less than 40% of TBSA

          -  Bleeding indicating treatment with rThrombin during the surgical procedure

          -  Females of child-bearing potential must have a negative urine or serum pregnancy test
             within 2 days prior to study-drug treatment

          -  informed consent document signed by legal representative (guardian) and approved by
             an institutional review board/independent ethics committee (IRB/IEC)

          -  Participant has signed an IRB/IEC-approved pediatric assent document, if applicable

        Exclusion Criteria:

          -  Gestational age younger than 36 weeks at birth (for infants younger than 2 years)

          -  Documented active infection at the graft recipient site (participants with resolved
             infections at potential graft recipient sites are not excluded)

          -  Acute inhalation injury, as defined by bronchoscopic evidence of lower airway injury

          -  Currently undergoing autologous skin grafting for ischemic ulcer disease or cutaneous
             malignancies

          -  Presence of antibodies or hypersensitivity to the study drug or any of its
             components, other thrombin preparations, or coagulation factors

          -  Transfusion of whole blood, fresh frozen plasma, cryoprecipitate, or platelets within
             24 hours prior to study-drug treatment (packed red blood cell transfusions are
             allowed)

          -  History of HIV infection or other immunodeficiency syndrome or is taking
             immunosuppressive or antirejection medications

          -  Medical, social, or psychosocial factors that, in the opinion of the investigator,
             could affect safety or compliance with study procedures

          -  Breastfeeding or being breastfed

          -  Treatment with any experimental agent within 30 days of study enrollment or treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Foster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Burn Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Burn Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 25, 2012</lastchanged_date>
  <firstreceived_date>March 9, 2009</firstreceived_date>
  <firstreceived_results_date>November 3, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 32 participants who signed informed consent in this study, 30 were actually enrolled and received treatment with rThrombin.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>rThrombin, 1000 IU/mL</title>
          <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rThrombin, 1000 IU/mL</title>
          <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>0-2 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>3-6 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>7-11 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>12-17 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian/Alaskan native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Death, Serious Adverse Events, Treatment-related Adverse Events (AE), AEs Leading to Discontinuation, and AEs of Hypersensitivity</title>
        <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment</description>
        <time_frame>Days 1 through 29, continuously</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Death, Serious Adverse Events, Treatment-related Adverse Events (AE), AEs Leading to Discontinuation, and AEs of Hypersensitivity</title>
            <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Deaths</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious adverse events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment-related adverse events (AEs)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs leading to discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs of hypersensitivity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs by Maximum Severity</title>
        <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. Mild=asymptomatic or minor symptoms; intervention not indicated. Moderate=requiring only minimal, local, or noninvasive intervention. Severe=significant symptoms but not life-threatening; hospitalization or invasive intervention indicated. Life-threatening=indicating intensive care or urgent invasive intervention.</description>
        <time_frame>Days 1 through 29, continuously</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With AEs by Maximum Severity</title>
            <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. Mild=asymptomatic or minor symptoms; intervention not indicated. Moderate=requiring only minimal, local, or noninvasive intervention. Severe=significant symptoms but not life-threatening; hospitalization or invasive intervention indicated. Life-threatening=indicating intensive care or urgent invasive intervention.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mild (0-2 years, n=11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild (3-6 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild (7-11 years, n=3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild (12-17 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate (0-2 years, n=11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate (3-6 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate (7-11 years, n=3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate (12-17 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe (0-2 years, n=11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe (3-6 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe (7-11 years, n=3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe (12-17 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Life-threatening (0-2 years, n=11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Life-threatening (3-6 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Life-threatening (7-11 years, n=3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Life-threatening (12-17 years, n=8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants WIth Positive Findings for Anti-rThrombin Product Antibody</title>
        <description>Antibody-positive was defined as seroconversion or ≥1.0 unit (≥10-fold) increase in titer compared with antibody titer at baseline.</description>
        <time_frame>At Day 29</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received study drug and had both baseline and on-treatment anti-rThrombin product antibody assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants WIth Positive Findings for Anti-rThrombin Product Antibody</title>
            <description>Antibody-positive was defined as seroconversion or ≥1.0 unit (≥10-fold) increase in titer compared with antibody titer at baseline.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Findings of Grade O or Higher in Platelet, White Blood Cell (WBC), Lymphocyte, and Neutrophil Counts</title>
        <description>Abnormal laboratory findings were recorded as AEs when considered clinically significant (unusual for the surgical population or individual participant) by the investigator, when associated with symptoms, when requiring specific treatment, or when requiring a change in participant management.LLN=lower level of normal. Platelets: Grade 0=normal. WBC: Grade 0=normal. Lymphocytes: Grade 0=normal; Grade 1=&lt;LLN x 0.8–10^9/L. Neutrophils: Grade 0=normal; Grade 1=&lt;LLN–1.5x10^9/L; Grade 2=&lt;1.5–1.0x10^9/L</description>
        <time_frame>Baseline and Day 29 from Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Clinical Laboratory Findings of Grade O or Higher in Platelet, White Blood Cell (WBC), Lymphocyte, and Neutrophil Counts</title>
            <description>Abnormal laboratory findings were recorded as AEs when considered clinically significant (unusual for the surgical population or individual participant) by the investigator, when associated with symptoms, when requiring specific treatment, or when requiring a change in participant management.LLN=lower level of normal. Platelets: Grade 0=normal. WBC: Grade 0=normal. Lymphocytes: Grade 0=normal; Grade 1=&lt;LLN x 0.8–10^9/L. Neutrophils: Grade 0=normal; Grade 1=&lt;LLN–1.5x10^9/L; Grade 2=&lt;1.5–1.0x10^9/L</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 0, low platelets (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, low platelets (Day 29, N=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, low WBC (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, low WBC (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, low lymphocytes (Baseline, N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, low lymphocytes (Day 29, N=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1, low lymphocytes (Baseline, N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1, low lymphocytes (Day 29, N=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, neutrophils (Baseline, N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0, neutrophils (Day 29, N=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2, low neutrophils (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2, low neutrophils (Day 29, N=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Hemoglobin Levels</title>
        <description>LLN=lower level of normal. Grade 1=100 g/L to &lt;LLN; Grade 2=80 to &lt;100 g/L; Grade 3=65 to &lt;80 g/L; Grade 4=&lt;65 g/L.</description>
        <time_frame>Baseline and Day 29 from Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Hemoglobin Levels</title>
            <description>LLN=lower level of normal. Grade 1=100 g/L to &lt;LLN; Grade 2=80 to &lt;100 g/L; Grade 3=65 to &lt;80 g/L; Grade 4=&lt;65 g/L.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 1 low hemoglobin (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 low hemoglobin (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2 low hemoglobin (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 2 low hemoglobin (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 low hemoglobin (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 low hemoglobin (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 4 low hemoglobin (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 4 low hemoglobin (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Creatinine Levels</title>
        <description>ULN=upper level of normal. Grade 0=normal; Grade 1=&gt;ULN to 1.5 x ULN.</description>
        <time_frame>Baseline and Day 29 from Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Clinical Laboratory Findings of Grade 0 or Higher in Creatinine Levels</title>
            <description>ULN=upper level of normal. Grade 0=normal; Grade 1=&gt;ULN to 1.5 x ULN.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 0 high creatinine (Baseline, N=30)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0 high creatinine (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 high creatinine (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 high creatinine (Day 29, N=26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Elevations in the Coagulation Parameter of Activated Partial Thromboplastin Time (aPPT)of Grade 0 or Higher</title>
        <description>ULN=upper limit of normal. Grade 0=normal; Grade 1=ULN to 1.5 x ULN.</description>
        <time_frame>Baseline and Day 29 from Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Elevations in the Coagulation Parameter of Activated Partial Thromboplastin Time (aPPT)of Grade 0 or Higher</title>
            <description>ULN=upper limit of normal. Grade 0=normal; Grade 1=ULN to 1.5 x ULN.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 0 high aPPT (Baseline, N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0 high aPPT (Day 29, N=24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 high aPPT (Baseline, N=29)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 1 high aPPT (Day 29, N=24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a High International Normalized Ratio (INR) of Prothrombin Time of Grade 0 or Higher</title>
        <description>Grade 0=normal.</description>
        <time_frame>Baseline and Day 29 from Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received treatment with rThrombin.</population>
        <group_list>
          <group group_id="O1">
            <title>rThrombin, 1000 IU/mL</title>
            <description>Recombinant thrombin (rThrombin), 1000 IU/mL, applied topically during a single surgery procedure on Day 1.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With a High International Normalized Ratio (INR) of Prothrombin Time of Grade 0 or Higher</title>
            <description>Grade 0=normal.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Grade 0 INR High (Baseline, N=28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 0 INR High (Day 29, N=24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TOTAL</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SKIN GRAFT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>SKIN GRAFT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>SKIN GRAFT FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>EXCESSIVE GRANULATION TISSUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>ZymoGenetics (ZG) agreements vary by trial, but each states that presentation/publication (p/p) cannot disclose Confidential Information (CI), excluding trial results; p/p may not begin until the earlier of 18 months after study end, ZG/lead investigator publishes, or ZG notification that multicenter publication is not planned; ZG has specified time for draft review before submission/presentation and may delay or modify content, require CI removal, and delay p/p for patent application filing.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Pribble, Vice President, Medical Affairs; Scot Maxon, Scientific Information</name_or_title>
      <organization>ZymoGenetics</organization>
      <phone>(206) 428-2756; (206) 434-3365</phone>
      <email>John.Pribble@bms.com; Scot.Maxon@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
